Stockscreener 앱 받기
15.56
3.39%
0.51
시간 외 거래:
15.56
전일 마감가:
$15.05
열려 있는:
$15.2
하루 거래량:
2.86M
Relative Volume:
0.80
시가총액:
$3.39B
수익:
$10.68M
순이익/손실:
$-272.71M
주가수익비율:
-9.9425
EPS:
-1.565
순현금흐름:
$-213.38M
1주 성능:
+15.34%
1개월 성능:
+27.54%
6개월 성능:
+93.77%
1년 성능:
+408.50%
1일 변동 폭
$15.19
$15.98
1주일 범위
$13.44
$15.98
52주 변동 폭
$2.98
$17.47
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
15.56 | 3.26B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Relay Therapeutics Q1 2026 earnings preview - MSN
Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why - Insider Monkey
[Form 4] Relay Therapeutics, Inc. Insider Trading Activity - Stock Titan
Relay Therapeutics (RLAY) director granted options on 32,947 shares at $14.09 - Stock Titan
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Relay Therapeutics (NASDAQ: RLAY) ups authorized common stock to 450M - Stock Titan
Relay Therapeutics prices $275M public offering of common stock at $12/share - MSN
RLAY News | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume - MSN
RLAY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Relay Therapeutics Hits Day High with 10.1% Surge in Strong Intraday Performance - Markets Mojo
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Relay Therapeutics Hits New 52-Week High of $17.46, Up 108.5% - MarketsMojo
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Relay Therapeutics stock hits 52-week high at 17.33 USD By Investing.com - Investing.com India
RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN
Relay Therapeutics Shares Surge 20% on ASCO Momentum for Zovegalisib Breast Cancer Program - International Business Times Australia
Relay Therapeutics stock hits 52-week high at 17.33 USD - Investing.com
Relay Therapeutics (RLAY) Valuation Check After Promising Zovegalisib Phase 2 Vascular Anomaly Data - simplywall.st
What Does Breakthrough Therapy Designation Mean for Relay Therapeutics - Kavout
Is Relay Therapeutics a Buy After Promising Trial Results? - AOL.com
RLAY Technical Analysis | Trend, Signals & Chart Patterns | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - 富途牛牛
Sector Update: Healthcare - Moomoo
Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June - Bez Kabli
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42 - MSN
Relay Therapeutics to present at two major healthcare investor conferences in June 2026 - Pluang
Relay Therapeutics leaders to join two June healthcare conferences - Stock Titan
Why Relay Therapeutics stock popped on Wednesday - MSN
RLAY Maintained by Guggenheim -- Price Target Raised to $26 - GuruFocus
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $28 - GuruFocus
H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data By Investing.com - Investing.com South Africa
Guggenheim raises Relay Therapeutics stock price target on drug profile By Investing.com - Investing.com Australia
H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data - Investing.com Australia
Guggenheim raises Relay Therapeutics stock price target on drug profile - Investing.com
Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26 - Moomoo
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28 - Moomoo
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) - MSN
Relay rises on mid-stage trial data for lead asset in vascular anomalies - MSN
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):